Purpose: To explore the role of CD15 expression in the prognosis of clear cell renal cell carcinoma (ccRCC) in Chinese patients. Methods: The study included 301 patients who had undergone surgery for localized ccRCC. All paraffin-embedded tumor sections were collected to make a set of tissue microarrays. CD15 expression was assessed by immunohistochemistry. The relationship between CD15 expression and survival parameters, clinicopathology features was assessed. Kaplan-Meier and Cox proportional hazards model were utilized to determine the correlation between CD15 expression and overall survival (OS). Results: The median follow-up time was 54.6 months (range, 3-121 months). The positive rate of CD15 expression was 81.7% (246/301). The cut-off value of CD15 expression was defined as the maximum for Youden index by plotting the receiver operating characteristic curve for survival status. As the threshold was 0.5, all cases were divided into two groups: positive expression group and negative expression group. In correlation analysis, loss of CD15 expression was correlated with female gender, higher Fuhrman nuclear grade, with sarcomatoid differentiation, with necrosis, and with vascular invasion. Kaplan-Meier analysis indicated that the OS time of patients with loss of CD15 expression was shorter than that of patients with positive CD15 expression (P = 0.013). Conclusion: CD15 is a significant prognostic factor in clear cell renal cell carcinoma.
Introduction
Renal cell carcinoma is the seventh most common cancer all over the world which causes almost 140,000 deaths per year (1) . Under renal cell carcinoma, clear cell renal cell carcinoma (ccRCC) is the most common subtype, and its incidence has increased steadily during the past decades (2) . Although most of the localized ccRCC patients can be cured by surgical resection, there are still many patients coming up with local recurrence and distant metastasis (3) . As metastatic ccRCC patients have various clinical outcomes (4) , the prognostic models that can explain the mechanism have not been fully constructed yet. According to Leibovich standard (5), many clinical and pathological features are associated with prognosis of localized RCCs that were undertaken nephrectomy, such as TNM stage, tumor size, nuclear grade, necrosis and symptoms. However, these prognostic models cannot always make accurate predictions due to the limitation of clinical factors and heterogeneity of tumors for cancer cell heterogeneity is thought to be one of the underlying reasons that make treatment of cancer difficult (6, 7) .
CD15, also known as SSEA-1, FUT-4 and Lewis-X, is the key enzyme in Lewis-Y molecules carried by glycoproteins and glycolipids, and Lewis-Y molecules are involved in fucosylation reactions, which is the most common glycosylation in carcinogenesis (8) (9) (10) . Previous studies showed that CD15 is expressed on the surface of neutrophils and is overexpressed in some pathophysiological processes, including bacterial infection, fertilization, inflammation and tumor invasion (11, 12) . Several studies have shown that CD15 expression is associated with prognosis and survival in a variety of cancers, such as breast cancer, Hodgkin's lymphoma, thyroid tumor and bile duct neoplasm (13) (14) (15) (16) . However, the mechanism of CD15 involved in tumorigenesis is still unclear.
The prognostic significance of Lewis X-related antigens in lowgrade RCC has been studied (17) , but with limitations (small amount of data with only 52 patients, confined to low grade (pT1-pT2) and few clinicopathologic parameters). In our study, we improved the process by collecting large amount of cases (N = 301) with complete clinicopathologic features and survival statistics to explore the expression of CD15 as a diagnostic and prognostic marker in ccRCC.
Patients and methods

Patients
In this study, 301 surgically resected ccRCC tissue samples were collected from Sun Yat-sen University Cancer Center between 2004 and 2012. The selection of the cases needed to meet the following criteria: histologically confirmed primary ccRCC; no neoadjuvant treatment before operation; underwent complete resection; without other malignant tumors and detailed clinical data, including overall survival (OS). The total clinicopathological data consist of gender, age at diagnosis, Fuhrman grade, necrosis, sarcomatoid differentiation, vascular invasion and TNM classification. 
Surveillance and follow-up
In our study, patients were under surveillance 2-3 times a year for the first 2 years after operation, and once a year for the following years.
Construction of the tissue microarray
Tissue microarray (TMA) was constructed using the common methods. In short, the paraffin-embedded tissue blocks and the corresponding histological H&E-stained slides were covered for tissue TMA sampling. Duplicates of 0.5 mm diameter cylinders were drilled from the chosen tumor areas of every specific donor tissue block, and re-embedded into a recipient paraffin block, using a tissue arraying instrument (Tissue Arrayer Minicore 3.0, Mitogen, British).
Immunohistochemistry
Formalin-fixed paraffin-embedded ccRCC samples were used for the immunohistochemical analyses. The tissue microarrays were sectioned at 4 μm and attached on adhesive glass slides. Primary antibody was anti-CD15 (Biocare Medical, clone MMA + BY87, mouse monoclonal, 1:100, Concord, CA, USA) and the immunohistochemistry (IHC) staining was completed by an automated stainer (Autostainerlink 48, Dako). Deparaffinization, antigen retrieval and immunostaining progress were performed in accordance with the manufacture's instruction using cell conditioning solutions and the diaminobenzidine (DAB) detection system. At last, after counterstaining with Mayer's hematoxylin, all sections were dehydrated and mounted.
IHC evaluation
The status of CD15 protein expression was assessed by microscopic observation of stained TMA slides. The staining of membranes and cytoplasm was considered to be positive for CD15 expression. In TMA sections, each spot contained two scores, which are the fraction of the intensity expression from negative to strong positivity as 0 = negative, 1 = weak positive expression, 2 = moderate positive expression, 3 = strong positive expression and the fraction of the expression area ranges from 0% to 100% (0 = 0-5%, 1 = 6-25%, 2 = 26-50%, 3 = 51-75%, 4 = 76-100%). The final total score was equal to the multiplied results of the intensity score and its corresponding area score for each patient. The status of CD15 expression was evaluated by two pathologists (C.Y. Wu and J.P. Huo) who were blind to the clinicopathological data for the patients.
Selection of cut-off score
Receiver operating characteristic (ROC) curves is a visualized plot that demonstrates the performance of a binary classifier system as its discrimination threshold is varied and provides an estimated of accuracy which can help determine the cut-off value for a particular diagnostic method (18) . Herein, for OS prediction, the ROC curve for sensitivity and specificity of the CD15 score was plotted. The optimal selection for cut-off value is the point on the ROC curve where the sensitivity and specificity are both the highest (19) . The score below or equal to the cut-off value was defined as low expression of CD15 while above the cut-off score was specified as high expression of CD15.
Statistical analyses
Statistical analyses were performed using SPSS software, version 19.0 (SPSS, Chicago, USA). The correlation between CD15 expression and clinicopathological features of ccRCC patients was assessed by Chi-square test. Univariate analysis of OS (the length of time from the date of surgery to either the date of death or the last follow-up date) data were calculated using the Kaplan-Meier method. And the Cox proportional hazards regression model was used to find the independent prognostic factors. All tests were two-tailed and P values less than 0.05 were used to prove statistically significant.
Results
Patients' characteristics
The clinicopathological characteristics of ccRCC patients are described in Table 1 . In this cohort, median age was 53 years (range, 4-83 years), and 68.4% of the patients were male. Thirty-six patients (11.9%) had pT3/T4 tumors and 76 patients (25.3%) had high-grade tumors. Average follow-up time was 54.6 months (median 51.6 months; range, 3-121 months).
CD15 expression and selection of the cut-off score
TMAs were subjected to H&E staining and IHC staining which showed that CD15 was expressed at various intensity levels on the membrane or in the cytoplasm of tumor cells (Fig. 1) . In all cases of ccRCC, 246 (81.7%) patients were detected CD15 positive. After comprehensive evaluation of IHC staining intensity and area, the ROC curve for OS was drawn, as well as the table of the sensitivity and '1-specificity' of each coordinates on the curve. According to Youden's index (20) , the cut-off value was found at 0.5 where the sensitivity and specificity can be simultaneously maximized. Due to the IHC score was 0-12 consecutive integer values, and the cut-off value was 0.5, all cases were divided into two groups, namely the positive expression group and the negative group. The evaluated score equal or above 1 was positive expression, while below 1 was negative expression or loss of CD15.
Association of CD15 expression with patients' clinicopathological features
In this study, positive expression of CD15 was statistically associated with male gender (P = 0.007), low Fuhrman nuclear grade (P = 0.006), without sarcomatoid differentiation (P = 0.010), without necrosis (P = 0.008), and without vascular invasion (P = 0.014). No association was observed between high expression of CD15 and age, lymph nodes invasion or T stage (Table 2 ). In CD15 positive expression group, the 5-year OS rate was 37.1% while in CD15 negative expression group, the 5-year OS rate dropped to 26.4%.
Univariate and multivariate survival analysis
Univariate analysis revealed a significant association between short OS and loss of CD15, elder age (>55 years), high Fuhrman nuclear grade (Grade 3/4), sarcomatoid differentiation, necrosis, vascular invasion, high T stage (pT3/T4) and lymph nodes invasion (pN1) ( Table 3) .
Eight variables performing a significant effect on OS were included in the multivariate analysis. Age (>55 years), high Fuhrman nuclear grade (Grade 3/4), high T stage (pT3/T4) and lymph nodes invasion (pN1) were largely associated with short OS (Table 3) . However, in multivariate analysis, the expression of CD15 was not related to OS. The relationship between CD15 expression and ccRCC patients' survival Loss of CD15 expression meant significantly shorter OS than positive expression of CD15 (Fig. 2) . Median 5-year survival time of positive expression of CD15 group was 52.95 months, while median 5-year survival time dropped to 48.60 months in negative expression of CD15 group. In stratified survival analysis, loss of CD15 expression was associated with shorter OS in younger patients (age ≤ 55 years), male gender, low stage of T staging (I-II), pathological characteristics of necrosis and lymph nodes invasion negative (Fig. 3) .
Discussion
As far as we know, this is the first study in Chinese patients to identify loss of CD15 expression as a poor prognostic factor for OS after nephrectomy for ccRCC. In this study, there were 246 patients with expression of CD15 (81.7%) suggesting that CD15 can be used as a diagnostic marker of ccRCC. In addition, loss of CD15 reduced the 5-year OS rate from 37.1% to 26.4%. CD15 positive expression was associated with male of gender, lower Fuhrman nuclear grade, without sarcomatoid differentiation, without necrosis and without vascular invasion. As demonstrated above, patients with loss of CD15 expression had largely decreased survival time compared to those with positive CD15 expression. Unfortunately, upon current clinicopathological statistics, Cox proportion hazards model analysis indicated that CD15 expression was not an independent predictor of prognosis for patients with ccRCC.
CD15 is a group of differentiation antigen, an immunologically significant molecule which expresses on the membrane as a kind of carbohydrate adhesion molecule. CD15 broadly participates in a variety of physiological processes, such as cell-to-cell recognition processes (21) , glycosylation process (8), mediating phagocytosis and chemotaxis which is often found on neutrophils (22) . In addition, CD15 is a significant marker of tumor stem cells (24) and tumor-propagating cells (TPCs) (23) . In pathological diagnosis, CD15 is commonly used in Hodgkin's lymphoma, some B-cell chronic lymphocytic leukemias and acute lymphoblastic leukemias (25) .
In epithelial tumors, CD15 is also widely expressed and often used as a diagnostic and prognostic marker. Many clinical studies have reported that high expression of CD15 in cancer cells is associated with tumor invasion and poor prognosis, such as colorectal cancer, pancreatic cancer, cholangiocarcinoma, thyroid cancer, non-small cell lung cancer, bladder cancer and breast cancer (14, 15, (26) (27) (28) (29) (30) . In colorectal cancer, high expression of CD15 on tumor cells means low levels of intratumoral CD8 + TILs and high systemic inflammation and indicated poorer outcomes in terms of progression-free survival (31). Giordano et al. had reported that overexpression of CD15 by colorectal cancer cells was subordinate to immune resistance as driven by oncogenic RAF-MEK-ERK kinase signaling through ERBB2 or FGFR4 activation (32) . In gastric cancer, overexpression of CD15 predicts poorer outcome by promoting Helicobacter pylori's adhesion and inducing immune escape (8, 10) . And in medulloblastoma, CD15 may represent an important marker for TPCs (23) .
However, the role of CD15 in renal cell carcinoma is still controversial. Fukushi et al. put forward that high expression of Lewis X (SSEA-1) was a good predictor of clinical prognosis and in their study 47 RCC patients were recruited to identify the function of fucosyl type 2 carbohydrate antigen family including Lewis X and sialyl Lewis X in generating better outcome in RCC patients (33) . Interestingly, another study organized by Tozawa et al. reported that high expression of sialyl Lewis X is associated with metastases and recurrences; in which only 45 Japanese patients were included (34) . Another research using FH6 and CSLEX-1 antibody explored the capacity of expression of sialyl Lewis X antigen as a predictor of prognosis in 52 low-stage (pT1/2) RCC (16) . Although both belong to fucosyl type 2 carbohydrate antigen family, Lewis X (CD15) and sialyl Lewis X (CD15s) have different structures, appear in different steps of in organ formation and have different functions in tumor biological process. In addition to this, all above studies were small scales involving only Japanese population, among which the biggest sample size was 52, and none of them carried out the mechanism of CD15 in RCC. In order to explore the diagnostic and prognostic effects of CD15 in Chinese patients with ccRCC, in this study, we used a large sample of patients including complete clinicopathological parameters and survival statistics from over 5-years follow-up. Previous studies reported that CD15 was found on proximal tubules in the normal kidney (35) and the NordiQC external quality assessment had confirmed this. In our research, CD15 was highly expressed in normal proximal tubules cortex and in different degrees on ccRCC. Using the same clone (MMA and BY87), Røge et al. stated that CD15 was detected in most cases of ccRCC (60-80%) (36) which was consistent with our findings (81%). Based on that RCC originated from proximal tubule epithelium (37) , it is assumed that RCC cells lacking differentiation antigens, such as CD15, can be observed as poor differentiated cells and those cells might have higher malignant potential than those expressing differentiation antigens. Our research data can improve this point. In this study, positive expression of CD15 is directly associated with long OS time. In young men patients (age ≤55 years) with low T staging (T1/2), without lymph nodes invasion, high expression of CD15 has a significant impact in guiding better prognosis. Although CD15 was not an independent predictor of prognosis in the Cox multivariate model, in the correlation analysis, high expression of CD15 was related to a number of better tumor differentiation indicators such as low Fuhrman nuclear grade (Grade 1/2), without sarcomatoid differentiation and without necrosis. Therefore, we speculate that loss of CD15 expression indicating poorer prognosis was achieved by decreasing the differentiation of ccRCC.
To our best knowledge, this is the biggest sample size to explore the relationship between CD15 and ccRCC prognosis. Although our study contained complete clinicopathological and prognostic data for 301 patients, we need more multi-center, large-sample data in order to get more convincing findings in Chinese population.
In conclusion, loss of CD15 expression is a strong prognostic factor for short OS in Chinese patients with localized ccRCC who had undergone nephrectomy and the expression intensity may be used to stratify the patients for further treatment.
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